… with immunomodulatory agents … immunomodulating agents, including neutralizing monoclonal
antibodies, corticosteroids, and other molecules in the management of severe COVID-19, …

… be considered as a potential therapeutic target against severe COVID-19. Consequently,
the proposal to treat severe COVID-19 with immunomodulatory therapy as it is done in HPS is …

… The aim of this project was to elaborate EULAR points to consider (PtCs) on COVID-19
pathophysiology and immunomodulatory therapies from the rheumatology perspective through a …

… Although few patients with severe COVID-19 would meet criteria for MAS, it is proposed that
they are on the spectrum and that MAS or secondary HLH therapies might be of benefit. IL-1 …

… COVID-19 patients. In this review, we will explore the evidence that has accumulated from
the use of immunomodulating therapies for COVID-19 … the IDSA guidelines for COVID-19 (4): …

… immunomodulatory therapies might be associated with improvements in a composite of death
or hospital admission due to COVID-19 [… from patients receiving immunomodulatory drugs …

… COVID-19. Corticosteroids are among the most commonly used drugs for immunomodulatory
therapy of … However, the use of corticosteroids in the treatment of COVID-19 can cause host …

… immunomodulatory therapies especially appealing as therapeutic approach in post-transplant
COVID-19. … safety of immunomodulatory therapies for the treatment of COVID-19 in SOT …

… patients, along with appropriate timing, duration, and dosage of the therapies. Therefore,
this review indicates that immunomodulatory therapies are potentially effective for COVID-19 …

… The aim of this project was to update the EULAR points to Consider (PtC) on the use of
immunomodulatory therapies in COVID-19 from the rheumatology perspective through a …